Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is a precision medicine oncology company whose news flow is driven by clinical trial milestones, regulatory interactions, strategic collaborations, and corporate updates. The company regularly issues press releases detailing progress across a deep pipeline of targeted small molecules and antibody-drug conjugates (ADCs) for molecularly defined solid tumors.
News related to IDYA often highlights developments in its lead program darovasertib, an oral protein kinase C inhibitor in clinical trials for uveal melanoma. Updates include enrollment milestones, progression-free survival and overall survival data from trials such as OptimUM-01 and OptimUM-02 in metastatic uveal melanoma, and neoadjuvant data from OptimUM-09 and the Phase 3 OptimUM-10 trial in primary uveal melanoma. IDEAYA also reports on regulatory designations for darovasertib and its collaboration with Servier for rights outside the United States.
Investors following IDEAYA news will see frequent announcements on its broader pipeline, including IDE397 for MTAP-deleted urothelial cancer and NSCLC, IDE849 for small cell lung cancer and neuroendocrine carcinomas, IDE161 as a PARG inhibitor for ADC combinations, IDE034 as a bispecific B7H3/PTK7 TOP1 ADC, IDE574 as a KAT6/7 dual inhibitor, and IDE892 as a PRMT5 inhibitor. Press releases cover IND submissions and clearances, Phase 1 and Phase 2 data readouts, and plans for upcoming medical conference presentations.
IDYA news also includes financial results, cash runway commentary, licensing transactions such as the Servier darovasertib agreement, and governance or compensation updates reported via SEC filings and corporate press releases. Tracking this news stream provides insight into IDEAYA’s clinical progress, partnering activity, and evolving precision oncology strategy.
IDEAYA Biosciences (NASDAQ: IDYA) announced its inaugural Synthetic Lethality Investor Day scheduled for April 20, 2021, from 1:00 pm to 3:00 pm ET. The virtual event will feature presentations from key opinion leaders and scientists from IDEAYA and GlaxoSmithKline (GSK), focusing on synthetic lethality in precision medicine. Topics include IDE397 targeting MAT2A in MTAP-deleted tumors and innovative cancer treatment strategies. Registration details are available on IDEAYA's website.
IDEAYA Biosciences (NASDAQ: IDYA) announced promising results from its ongoing Phase 1/2 trial of darovasertib (IDE196) for treating solid tumors, including Metastatic Uveal Melanoma (MUM). Key findings include a 57% one-year overall survival rate in heavily pre-treated MUM patients, compared to a historical rate of 37%. Additionally, 61% of MUM patients showed tumor reduction. The combination therapy with binimetinib also yielded early results, with 22% of MUM patients showing partial responses. The company continues its clinical development focus and will host an investor webcast for further insights.
IDEAYA Biosciences (NASDAQ: IDYA) announced an upcoming webcast on April 16, 2021, to discuss clinical data from its Phase 1/2 trial evaluating darovasertib (IDE196) as monotherapy and in combination with binimetinib for treating metastatic uveal melanoma. The company will host an Investor Day featuring leading clinical investigators. Additionally, the International Nonproprietary Name for IDE196 has been confirmed as darovasertib by WHO. The press release cautions investors about risks in drug development and the potential impacts of COVID-19 on business operations.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) has announced the dosing of the first patient in its Phase 1 clinical trial of IDE397, a methionine adenosyltransferase 2a (MAT2A) inhibitor, targeting patients with methylthioadenosine phosphorylase (MTAP) deletion, which occurs in about 15% of solid tumors. IDE397 has shown promising anti-tumor activity across various solid tumor types, including non-small cell lung cancer and gastric cancer. The trial's progress involves activating multiple clinical sites in the U.S. and using Next Generation Sequencing for patient identification.
IDEAYA Biosciences (Nasdaq:IDYA) provided a business update and reported financial results for Q4 2020. The company advanced IDE397 into Phase 1 for treating solid tumors with MTAP deletions, representing about 15% of all solid tumors. IDEAYA's pipeline includes significant progress in IDE196 and plans for Development Candidate nominations for PARG and Pol Theta programs in 2021. Financially, IDEAYA reported a net loss of $5.1 million for Q4 2020, improved from $10.8 million in Q4 2019, and held $283.6 million in cash and equivalents as of December 31, 2020.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced a dose expansion of its Phase 1/2 study evaluating the combination of IDE196 and binimetinib in metastatic uveal melanoma (MUM). Early clinical activity has shown promise, with plans to enroll approximately 40 patients. IDEAYA received a Notice of Allowance for a U.S. patent covering this combination therapy. The company targets interim data updates in 2021, including tolerability and clinical efficacy from both the combination and monotherapy arms, which may reveal clinical activity independent of HLA status.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced the publication of abstracts for its synthetic lethality programs at the 2021 AACR Annual Meeting. The company will present data on IDE397, a MAT2A inhibitor, and IDE196, a PKC inhibitor targeting certain cancers. IDE397 is currently in a Phase 1 trial targeting tumors with MTAP deletion, while IDE196 is in Phase 1/2 trials for metastatic uveal melanoma and skin melanoma. The presentations will also cover preclinical data on the efficacy of these treatments and their potential combinations with other therapies.
IDEAYA Biosciences (NASDAQ: IDYA), a company focused on precision medicine in oncology, announced its participation in several significant investor relations events in March 2021. These include the H.C. Wainwright Global Life Sciences Conference on March 9, Citi's Winter West Coast Biotech Virtual Bus Tour on March 16, and Oppenheimer's Healthcare Conference on March 17. A live audio webcast will be accessible through the IDEAYA website, and recordings will be available for 30 days post-event. IDEAYA specializes in developing targeted therapeutics using synthetic lethality.
IDEAYA Biosciences (NASDAQ: IDYA) announced its first Synthetic Lethality Investor Day, scheduled for April 20, 2021. This virtual event will feature presentations from IDEAYA, GlaxoSmithKline (GSK), and key academic leaders. The agenda includes discussions on IDEAYA's synthetic lethality programs, particularly IDE397, a Phase 1 clinical trial targeting MAT2A in MTAP-deleted tumors, a condition found in around 15% of solid tumors. The event aims to engage scientific and investor communities regarding advancements in precision medicine.
IDEAYA Biosciences (NASDAQ: IDYA) announced the appointment of Dr. Susan Kelley to its Board of Directors, enhancing its leadership in oncology research. Dr. Kelley brings over 25 years of experience, notably as Chief Medical Officer at the Multiple Myeloma Research Consortium, and previous roles at Bayer and Bristol-Myers Squibb. Her expertise will support the advancement of IDEAYA's clinical programs, including the Phase 1 IDE397 and potential Phase 2 expansion for IDE196. This strategic addition aims to strengthen IDEAYA's pipeline of precision medicine oncology therapies.